Effectiveness and safety of eprosartan on pulse pressure for the treatment of hypertensive patients

Summary A multicentre, prospective, non‐comparative open‐label study was conducted to assess the effect of eprosartan, 600 mg/day, on pulse pressure (PP) in patients with hypertension (stage I or II, Joint National Committee, sixth report) treated in the primary care setting, as well as safety and c...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of clinical practice (Esher) 2005-04, Vol.59 (4), p.478-484
Hauptverfasser:	Robles, N. R., Martín-Águeda, B., López-Muñoz, F., Álamo, C.
Format:	Artikel
Sprache:	eng
Schlagworte:	Acrylates - adverse effects Acrylates - therapeutic use Adult Aged Antihypertensive Agents - adverse effects Antihypertensive Agents - therapeutic use Biological and medical sciences Blood Pressure - drug effects Clinical trials Drug therapy eprosartan Female General aspects Humans Hypertension Hypertension - drug therapy Hypertension - physiopathology Imidazoles - adverse effects Imidazoles - therapeutic use Male Medical sciences Middle Aged Prospective Studies Pulse pulse pressure Side effects Thiophenes - adverse effects Thiophenes - therapeutic use Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Summary A multicentre, prospective, non‐comparative open‐label study was conducted to assess the effect of eprosartan, 600 mg/day, on pulse pressure (PP) in patients with hypertension (stage I or II, Joint National Committee, sixth report) treated in the primary care setting, as well as safety and compliance. The duration of treatment was 16 weeks. Eprosartan decreased PP (−13 mmHg), systolic blood pressure (SBP) (−26 mmHg), diastolic blood pressure (DBP) (−13 mmHg) and mean arterial pressure (MAP) (−17.4 mmHg) significantly (p
ISSN:	1368-5031 1742-1241
DOI:	10.1111/j.1368-5031.2005.00515.x